osiris
-
Biologics
Osiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors
COLUMBIA, Md. , Feb. 10, 2017 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ:OSIR) is pleased to announce that its Board…
Read More » -
Financial
Osiris Provides Update Regarding NASDAQ Listing Matters
COLUMBIA, Md., Dec. 02, 2016 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”) today provided an update regarding the…
Read More » -
Financial
Osiris Therapeutics, Inc. Reports Preliminary 2014 and 2015 Revenue and Anticipated 2016 Revenue
COLUMBIA, Md., Nov. 07, 2016 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing…
Read More » -
Biologics
Osiris Therapeutics Announces Appointment of Alberto Avendano, M.D. as Chief Medical Officer
COLUMBIA, Md., Oct. 06, 2016 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has appointed R. Alberto Avendano, M.D., as the Company’s…
Read More » -
Financial
Osiris Provides Update Regarding NASDAQ Listing Status
COLUMBIA, Md., Sept. 16, 2016 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”) provided today an update concerning the status of its compliance…
Read More » -
Financial
Osiris Provides Update Regarding NASDAQ Listing Matters
COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”), today provided an update regarding the status of its compliance with…
Read More » -
Biologics
MiMedx Comments on Flawed Osiris Data Review
MARIETTA, Ga., May 3, 2016 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes…
Read More » -
Osiris to Present 15 Advanced Clinical and Scientific Abstracts
COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to…
Read More » -
Hospitals
Osiris Therapeutics : receives deficiency notice from Nasdaq
March 23–Osiris Therapeutics Inc., the troubled Columbia-based biotechnology firm that saw its CEO resign last month, said Tuesday it has…
Read More » -
Osiris Provides an Update on a Clinical Review by Blue Cross Blue Shield Association
COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing…
Read More » -
Extremities
Grafix Demonstrates Positive Clinical Outcomes in Chronic Complex Wounds with Exposed Tendon and Bone
COLUMBIA, Md.–(BUSINESS WIRE)–Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to…
Read More » -
Biologics
Osiris Provides Update on Coverage for Grafix®
Grafix gets confirmed Medicare coverage from Cahaba effective January 1 and signs contract with major GPO COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading cellular…
Read More » -
Sports Medicine
Osiris Announces Initiation of a Phase III Trial for a New Investigational Drug, OTI-15-01, for the Treatment of Chronic Diabetic Foot Wounds
COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat…
Read More » -
Biologics
STRYKER GET EXCLUSIVE RIGHTS TO OSIRIS BONE ALLOGRAFT
Walter Eisner • Mon, December 29th, 2014 Osiris Therapeutics, Inc. and Stryker Corporation have entered into an exclusive, worldwide partnership…
Read More » -
Biologics
Osiris Therapeutics (OSIR), Arthrex Enter Exclusive Partnership Covering Cartiform
Osiris Therapeutics (Nasdaq: OSIR) has entered into an exclusive commercial and development partnership for its cartilage product, Cartiform, with Arthrex,…
Read More »